[P02BB01, trichlorfon, Metrifonate may increase the bradycardic activities of Propafenone.]
[S02DA03, antipyrine, Antipyrine may decrease the antihypertensive activities of Propafenone.]
[L04AA27, fingolimod, Propafenone may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Propafenone.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Propafenone.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Propafenone.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Propafenone.]
[M01AB02, sulindac, Sulindac may decrease the antihypertensive activities of Propafenone.]
[N05AL01, sulpiride, Sulpiride may increase the bradycardic activities of Propafenone.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Propafenone.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Propafenone.]
[M01AX04, apazone, Azapropazone may decrease the antihypertensive activities of Propafenone.]
[L01BB02, mercaptopurine, The serum concentration of Mercaptopurine can be increased when it is combined with Propafenone.]
[N06DA01, tacrine, Tacrine may increase the bradycardic activities of Propafenone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Propafenone.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Propafenone.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Propafenone.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Propafenone.]
[N05AE05, lurasidone, The risk or severity of hypertension can be increased when Propafenone is combined with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Propafenone can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Propafenone.]
[R03DA07, theobromine, The serum concentration of Theobromine can be increased when it is combined with Propafenone.]
[R03DA04, theophylline, The serum concentration of Theophylline can be increased when it is combined with Propafenone.]
[P02CA02, thiabendazole, The metabolism of Propafenone can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Propafenone.]
[R06AD03, thiethylperazine, The serum concentration of Propafenone can be increased when it is combined with Thiethylperazine.]
[L01AC01, thiotepa, Thiotepa may increase the bradycardic activities of Propafenone.]
[N05CA19, thiopental, The serum concentration of Propafenone can be decreased when it is combined with Thiopental.]
[N05AB08, thioproperazine, The serum concentration of Propafenone can be increased when it is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Thioridazine.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be decreased when combined with Propafenone.]
[C01BB04, aprindine, Propafenone may increase the arrhythmogenic activities of Aprindine.]
[B02AB01, aprotinin, Aprotinin may increase the bradycardic activities of Propafenone.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Propafenone is combined with Moxisylyte.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Propafenone.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Propafenone.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Propafenone.]
[M02AX02, tolazoline, Propafenone may increase the orthostatic hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Propafenone.]
[M02AA21, tolmetin, Tolmetin may decrease the antihypertensive activities of Propafenone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Propafenone.]
[N06AF04, tranylcypromine, The metabolism of Propafenone can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Propafenone.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Propafenone.]
[C03AA06, trichlormethiazide, Propafenone may decrease the antihypertensive activities of Trichlormethiazide.]
[S01EB04, demecarium, Demecarium may increase the bradycardic activities of Propafenone.]
[N05AB06, trifluoperazine, The serum concentration of Propafenone can be increased when it is combined with Trifluoperazine.]
[N05AA05, triflupromazine, The serum concentration of Propafenone can be increased when it is combined with Triflupromazine.]
[A03AA05, trimebutine, Propafenone may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Propafenone may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The serum concentration of Propafenone can be increased when it is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Propafenone.]
[C02BA01, trimethaphan, Propafenone may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Propafenone.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Propafenone.]
[R06AC04, tripelennamine, The metabolism of Propafenone can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Propafenone.]
[J01FA08, troleandomycin, The metabolism of Propafenone can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Propafenone can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Propafenone may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the bradycardic activities of Propafenone.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Propafenone.]
[S01AA05, tyrothricin, Tyrothricin may increase the bradycardic activities of Propafenone.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Vandetanib.]
[L02BX03, abiraterone, The serum concentration of Propafenone can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Propafenone.]
[J05AP03, boceprevir, The metabolism of Propafenone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Propafenone can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Propafenone can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Propafenone.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Propafenone.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Propafenone.]
[B01AC24, ticagrelor, The serum concentration of Ticagrelor can be increased when it is combined with Propafenone.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Propafenone.]
[N06AX09, viloxazine, The metabolism of Propafenone can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Propafenone.]
[C04AX07, vincamine, Propafenone may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Propafenone.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Propafenone.]
[S01AA13, fusidic acid, The metabolism of Propafenone can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Propafenone is combined with Xenon.]
[C03BA10, xipamide, Propafenone may decrease the antihypertensive activities of Xipamide.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Propafenone.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Propafenone can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Propafenone can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Propafenone.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propafenone.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Drospirenone.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Propafenone.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Propafenone.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Propafenone.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Atenolol.]
[L03AB11, peginterferon alfa-2a, The metabolism of Propafenone can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Propafenone can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Propafenone.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Propafenone.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Propafenone.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Propafenone.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Propafenone.]
[A08AA11, lorcaserin, The metabolism of Propafenone can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The metabolism of Propafenone can be decreased when combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Propafenone.]
[V03AX03, cobicistat, The metabolism of Propafenone can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Propafenone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Propafenone can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Propafenone.]
[L04AA31, teriflunomide, The serum concentration of Propafenone can be decreased when it is combined with Teriflunomide.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Propafenone.]
[L01EX05, regorafenib, Regorafenib may increase the bradycardic activities of Propafenone.]
[N05CA04, barbital, The serum concentration of Propafenone can be decreased when it is combined with Barbital.]
[C01AA01, acetyldigitoxin, The serum concentration of Acetyldigitoxin can be increased when it is combined with Propafenone.]
[J05AE04, nelfinavir, The metabolism of Propafenone can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Propafenone.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be decreased when combined with Propafenone.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Propafenone.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Propafenone.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Propafenone.]
[L04AA29, tofacitinib, Propafenone may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Propafenone.]
[G04BD10, darifenacin, The metabolism of Propafenone can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Propafenone is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Propafenone.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Propafenone.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Propafenone.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Propafenone.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Bedaquiline.]
[C04AX11, bencyclane, Propafenone may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Propafenone.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Propafenone can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Propafenone may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Propafenone.]
[G03XC05, ospemifene, The metabolism of Propafenone can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the antihypertensive activities of Propafenone.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propafenone.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Propafenone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Propafenone.]
[A06AX06, tegaserod, The metabolism of Propafenone can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Propafenone.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Propafenone.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Propafenone.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Propafenone.]
[M01AH01, celecoxib, Celecoxib may decrease the antihypertensive activities of Propafenone.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Naratriptan is combined with Propafenone.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Propafenone.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Propafenone.]
[L01EC02, dabrafenib, The serum concentration of Propafenone can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the antihypertensive activities of Propafenone.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Propafenone.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Propafenone.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Propafenone.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Propafenone.]
[C08EA02, bepridil, Propafenone may increase the arrhythmogenic activities of Bepridil.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Propafenone.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Propafenone.]
[C02KX04, macitentan, Propafenone may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Propafenone.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Propafenone.]
[J05AP05, simeprevir, The metabolism of Propafenone can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Propafenone.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Propafenone.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Propafenone.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Propafenone.]
[A16AA07, metreleptin, The metabolism of Propafenone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Propafenone can be increased when combined with Apremilast.]
[A16AA06, betaine, Betaine may increase the bradycardic activities of Propafenone.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Betaxolol.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Propafenone.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Propafenone.]
[L04AC11, siltuximab, The metabolism of Propafenone can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Propafenone may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Propafenone.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Propafenone.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Propafenone.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Propafenone.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propafenone.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Propafenone.]
[A16AX10, eliglustat, The metabolism of Propafenone can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Propafenone can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The serum concentration of Propafenone can be increased when it is combined with Acepromazine.]
[V04CX03, methacholine, Propafenone may increase the bronchoconstrictory activities of Methacholine.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Propafenone.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Propafenone.]
[N04AA02, biperiden, The metabolism of Propafenone can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Propafenone.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Propafenone.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Propafenone.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Propafenone.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be decreased when combined with Propafenone.]
[L04AC10, secukinumab, The metabolism of Propafenone can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Propafenone can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Propafenone.]
[C01EB17, ivabradine, Propafenone may increase the bradycardic activities of Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Propafenone can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Propafenone.]
[A04AD14, rolapitant, The metabolism of Propafenone can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Propafenone is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Propafenone is combined with Cariprazine.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Propafenone.]
[M02AA25, aceclofenac, Aceclofenac may decrease the antihypertensive activities of Propafenone.]
[M01AB11, acemetacin, Acemetacin may decrease the antihypertensive activities of Propafenone.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Propafenone.]
[N05AB07, acetophenazine, The serum concentration of Propafenone can be increased when it is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Propafenone can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Propafenone.]
[J02AC05, isavuconazole, The metabolism of Propafenone can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Propafenone can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Propafenone.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Propafenone.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Propafenone.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Propafenone.]
[G04CA01, alfuzosin, Propafenone may increase the orthostatic hypotensive activities of Alfuzosin.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Propafenone.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Propafenone.]
[M01AE16, alminoprofen, Alminoprofen may decrease the antihypertensive activities of Propafenone.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Propafenone.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Propafenone.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Propafenone.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Propafenone.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Propafenone is combined with Amineptine.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Propafenone.]
[A05AA04, obeticholic acid, The metabolism of Propafenone can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The serum concentration of Bupivacaine can be increased when it is combined with Propafenone.]
[C07AA19, bupranolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Propafenone.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Propafenone.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Propafenone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Propafenone may increase the bradycardic activities of Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Propafenone.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Propafenone.]
[L01XK03, rucaparib, The metabolism of Propafenone can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Propafenone.]
[L01EF02, ribociclib, The metabolism of Propafenone can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the antihypertensive activities of Propafenone.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Propafenone.]
[R03DA08, bamifylline, The serum concentration of Bamifylline can be increased when it is combined with Propafenone.]
[N07XX16, deutetrabenazine, The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Propafenone.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Propafenone.]
[N06BC01, caffeine, The serum concentration of Caffeine can be increased when it is combined with Propafenone.]
[C09AA07, benazepril, Propafenone may decrease the antihypertensive activities of Benazepril.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Propafenone.]
[A12AA04, calcium carbonate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium carbonate.]
[G04BA03, calcium chloride, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Propafenone.]
[J05AE09, tipranavir, The serum concentration of Propafenone can be increased when it is combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Propafenone.]
[L04AB02, infliximab, The metabolism of Propafenone can be increased when combined with Infliximab.]
[A12AA01, calcium phosphate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium Phosphate.]
[L01EX10, midostaurin, The metabolism of Propafenone can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Propafenone is combined with Safinamide.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Propafenone is combined with Bethanechol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Propafenone.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Propafenone.]
[P03AC02, bioallethrin, Propafenone may increase the arrhythmogenic activities of Bioallethrin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Propafenone is combined with Acetylcholine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Propafenone.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Propafenone.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Propafenone.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Propafenone.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Propafenone.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Propafenone.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Propafenone.]
[J05AG03, efavirenz, The metabolism of Propafenone can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Bopindolol.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Canrenone.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Propafenone is combined with Buflomedil.]
[M01AB07, bumadizone, Bumadizone may decrease the antihypertensive activities of Propafenone.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Propafenone.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Propafenone.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Propafenone.]
[N01BX04, capsaicin, Capsaicin may increase the bradycardic activities of Propafenone.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Propafenone.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Propafenone.]
[C09AA01, captopril, Propafenone may decrease the antihypertensive activities of Captopril.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Propafenone is combined with Carbamoylcholine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Propafenone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Propafenone can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium polycarbophil.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Propafenone.]
[L03AB06, interferon alfa-n1, The metabolism of Propafenone can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Propafenone is combined with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Propafenone can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Propafenone.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Propafenone.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Propafenone.]
[C07AB08, celiprolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Propafenone.]
[L01XX62, ivosidenib, The metabolism of Propafenone can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Propafenone.]
[N03AX17, stiripentol, The metabolism of Propafenone can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Propafenone.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Propafenone.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Propafenone.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Propafenone.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Propafenone.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Propafenone.]
[M01AC05, lornoxicam, Lornoxicam may decrease the antihypertensive activities of Propafenone.]
[R03DA02, oxtriphylline, The serum concentration of Oxtriphylline can be increased when it is combined with Propafenone.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Propafenone.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Propafenone.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Propafenone.]
[L04AA39, emapalumab, The metabolism of Propafenone can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Carmustine can be decreased when combined with Propafenone.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Propafenone.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Amifampridine.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Propafenone.]
[C01BG07, cifenline, Propafenone may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, Propafenone may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Propafenone.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Propafenone is combined with Cinitapride.]
[S01ED05, carteolol, Propafenone may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Propafenone.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Propafenone.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Propafenone is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Propafenone can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Propafenone.]
[N05BA09, clobazam, The metabolism of Propafenone can be decreased when combined with Clobazam.]
[V03AE07, calcium acetate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, Propafenone may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Propafenone can be increased when combined with Etanercept.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Propafenone.]
[N05AA06, cyamemazine, The serum concentration of Propafenone can be increased when it is combined with Cyamemazine.]
[C03BX03, cicletanine, Propafenone may increase the arrhythmogenic activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Propafenone.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Propafenone.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Pitolisant can be increased when it is combined with Propafenone.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Propafenone.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Propafenone.]
[C03AA09, cyclothiazide, Propafenone may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Propafenone.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Propafenone.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Propafenone.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Propafenone.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Propafenone.]
[N03AX25, cenobamate, The serum concentration of Propafenone can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Propafenone can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Propafenone.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Propafenone.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Propafenone.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Propafenone.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Propafenone.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Propafenone.]
[M01AX21, diacetylrhein, The metabolism of Propafenone can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Propafenone.]
[S01AE06, gatifloxacin, The metabolism of Propafenone can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Propafenone can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of Propafenone can be increased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be decreased when combined with Propafenone.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Propafenone.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Propafenone.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Propafenone.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Propafenone.]
[M01AH02, rofecoxib, Rofecoxib may decrease the antihypertensive activities of Propafenone.]
[C08CA16, clevidipine, Propafenone may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Propafenone may increase the arrhythmogenic activities of Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Propafenone.]
[C02AA06, methoserpidine, Propafenone may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Propafenone.]
[L01EX17, capmatinib, The metabolism of Propafenone can be decreased when combined with Capmatinib.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Propafenone.]
[G04BD09, trospium, The metabolism of Propafenone can be decreased when combined with Trospium.]
[M01AC04, droxicam, Droxicam may decrease the antihypertensive activities of Propafenone.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Propafenone.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Propafenone is combined with Selpercatinib.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the antihypertensive activities of Propafenone.]
[C08CA17, levamlodipine, The risk or severity of bradycardia can be increased when Levamlodipine is combined with Propafenone.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Propafenone.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Propafenone.]
[P01BB01, proguanil, The metabolism of Propafenone can be decreased when combined with Proguanil.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Propafenone.]
[L04AC19, satralizumab, The serum concentration of Propafenone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be increased when it is combined with Propafenone.]
[P01BA01, chloroquine, The metabolism of Propafenone can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Propafenone.]
[C03AA04, chlorothiazide, Propafenone may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Propafenone.]
[N05AA01, chlorpromazine, The metabolism of Propafenone can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Propafenone.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Propafenone.]
[C03BA04, chlorthalidone, Propafenone may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Propafenone.]
[A11CC05, cholecalciferol, The metabolism of Propafenone can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, Ethenzamide may decrease the antihypertensive activities of Propafenone.]
[N06BX18, vinpocetine, Propafenone may increase the arrhythmogenic activities of Vinpocetine.]
[M01AB08, etodolac, Etodolac may decrease the antihypertensive activities of Propafenone.]
[M02AA06, etofenamate, Etofenamate may decrease the antihypertensive activities of Propafenone.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Propafenone.]
[A16AX20, lonafarnib, The metabolism of Propafenone can be decreased when combined with Lonafarnib.]
[M09AA01, hydroquinine, Propafenone may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Propafenone.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Propafenone is combined with Naxitamab.]
[L04AD03, voclosporin, The serum concentration of Voclosporin can be increased when it is combined with Propafenone.]
[P03AX07, abametapir, The serum concentration of Propafenone can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Propafenone.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Propafenone.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Propafenone.]
[M01AE05, fenbufen, Fenbufen may decrease the antihypertensive activities of Propafenone.]
[N06BA10, fenethylline, The serum concentration of Fenethylline can be increased when it is combined with Propafenone.]
[C01CA19, fenoldopam, Propafenone may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Propafenone is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Propafenone is combined with Finasteride.]
[J01MB07, flumequine, The metabolism of Propafenone can be decreased when combined with Flumequine.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Propafenone.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Propafenone.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Propafenone.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Propafenone.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Propafenone is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Propafenone can be increased when it is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Propafenone may decrease the antihypertensive activities of Dasiglucagon.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Propafenone.]
[A02BA01, cimetidine, The serum concentration of Propafenone can be increased when it is combined with Cimetidine.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Propafenone.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Propafenone.]
[L01XX73, sotorasib, The serum concentration of Propafenone can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Propafenone can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Cisplatin may increase the bradycardic activities of Propafenone.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Propafenone can be increased when combined with Somapacitan.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Finerenone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Propafenone is combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The metabolism of Propafenone can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Mobocertinib.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Propafenone.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Clemastine.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the antihypertensive activities of Propafenone.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Propafenone.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Propafenone.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Propafenone.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium glubionate anhydrous.]
[N06AX25, St. John's wort extract, The serum concentration of Propafenone can be decreased when it is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Propafenone can be decreased when combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Propafenone.]
[N01BB10, levobupivacaine, The metabolism of Levobupivacaine can be decreased when combined with Propafenone.]
[L01EJ03, pacritinib, The metabolism of Propafenone can be decreased when combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Propafenone.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Propafenone.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Propafenone.]
[C01EB24, mavacamten, The serum concentration of Propafenone can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Propafenone.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Propafenone.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Propafenone.]
[L01XX77, adagrasib, The serum concentration of Propafenone can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The metabolism of Propafenone can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Propafenone.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Propafenone.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Propafenone.]
[H01AC08, somatrogon, The metabolism of Propafenone can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Cocaine.]
[C02KB01, metyrosine, Propafenone may decrease the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Propafenone can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the antihypertensive activities of Propafenone.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Propafenone.]
[M03AC05, hexafluorenium, Hexafluronium may increase the bradycardic activities of Propafenone.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Propafenone.]
[L04AA13, leflunomide, The serum concentration of Propafenone can be decreased when it is combined with Leflunomide.]
[C01BA13, hydroquinidine, Propafenone may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, The risk or severity of hypertension can be increased when Propafenone is combined with Desflurane.]
[A04AA03, tropisetron, Propafenone may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Propafenone is combined with Ifenprodil.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Propafenone.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the antihypertensive activities of Propafenone.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Propafenone.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Propafenone.]
[J01FA15, telithromycin, The metabolism of Propafenone can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Propafenone.]
[B01AC10, indobufen, Indobufen may decrease the antihypertensive activities of Propafenone.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Propafenone.]
[M01AH03, valdecoxib, Valdecoxib may decrease the antihypertensive activities of Propafenone.]
[H01AX01, pegvisomant, Pegvisomant may increase the bradycardic activities of Propafenone.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Propafenone.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Propafenone.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Propafenone.]
[M01AH04, parecoxib, Parecoxib may decrease the antihypertensive activities of Propafenone.]
[J02AC02, itraconazole, The metabolism of Propafenone can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Propafenone.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Propafenone.]
[M01AA06, kebuzone, Kebuzone may decrease the antihypertensive activities of Propafenone.]
[L01EA01, imatinib, The serum concentration of Propafenone can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Propafenone can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Propafenone may increase the arrhythmogenic activities of Lacidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Propafenone.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Propafenone.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Propafenone.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Propafenone.]
[M01AB09, lonazolac, Lonazolac may decrease the antihypertensive activities of Propafenone.]
[M02AA31, loxoprofen, Loxoprofen may decrease the antihypertensive activities of Propafenone.]
[C09AA03, lisinopril, Propafenone may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, Propafenone may increase the arrhythmogenic activities of Manidipine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Propafenone is combined with Mefenorex.]
[C07AA14, mepindolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Mepindolol.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Propafenone.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Propafenone.]
[C04AX01, cyclandelate, Propafenone may increase the arrhythmogenic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Propafenone.]
[C03DA04, eplerenone, Propafenone may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, Propafenone may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Propafenone may decrease the antihypertensive activities of Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Propafenone.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Propafenone.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Propafenone.]
[S01XA18, cyclosporine, The metabolism of Propafenone can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be decreased when combined with Propafenone.]
[N06BA07, modafinil, The metabolism of Propafenone can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Propafenone.]
[C09AA13, moexipril, Propafenone may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, Mofebutazone may decrease the antihypertensive activities of Propafenone.]
[M01AX22, morniflumate, Morniflumate may decrease the antihypertensive activities of Propafenone.]
[C03XA02, conivaptan, The metabolism of Propafenone can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Propafenone.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Propafenone.]
[G04BE09, vardenafil, The serum concentration of Vardenafil can be increased when it is combined with Propafenone.]
[M01AH05, etoricoxib, Etoricoxib may decrease the antihypertensive activities of Propafenone.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Propafenone.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Propafenone.]
[G03XA01, danazol, The metabolism of Propafenone can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Dantrolene.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Propafenone.]
[M01AX01, nabumetone, Nabumetone may decrease the antihypertensive activities of Propafenone.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Propafenone.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Propafenone can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Propafenone may increase the arrhythmogenic activities of Nicorandil.]
[C01CA23, theodrenaline, The serum concentration of Theodrenaline can be increased when it is combined with Propafenone.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Propafenone.]
[N06AB10, escitalopram, The serum concentration of Propafenone can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Propafenone.]
[A07EC03, olsalazine, Olsalazine may decrease the antihypertensive activities of Propafenone.]
[N06AA01, desipramine, The metabolism of Propafenone can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, The serum concentration of Deslanoside can be increased when it is combined with Propafenone.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Propafenone.]
[C09XA02, aliskiren, Propafenone may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Propafenone.]
[M01AE12, oxaprozin, Oxaprozin may decrease the antihypertensive activities of Propafenone.]
[S03BA01, dexamethasone, The metabolism of Propafenone can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Propafenone can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Propafenone.]
[L04AB04, adalimumab, The metabolism of Propafenone can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Propafenone.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Propafenone.]
[N06AB05, paroxetine, The metabolism of Propafenone can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Propafenone.]
[C04AD01, pentifylline, The serum concentration of Pentifylline can be increased when it is combined with Propafenone.]
[V03AH01, diazoxide, Propafenone may decrease the antihypertensive activities of Diazoxide.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Propafenone is combined with Dibenzepin.]
[S02DA04, dibucaine, Cinchocaine may increase the bradycardic activities of Propafenone.]
[S01BC03, diclofenac, Diclofenac may decrease the antihypertensive activities of Propafenone.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Propafenone.]
[C02DG01, pinacidil, Propafenone may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, Propafenone may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Propafenone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Propafenone.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Propafenone.]
[P02CB02, diethylcarbamazine, Diethylcarbamazine may increase the bradycardic activities of Propafenone.]
[A08AA03, diethylpropion, The therapeutic efficacy of Propafenone can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Propafenone.]
[N02BA11, diflunisal, Diflunisal may decrease the antihypertensive activities of Propafenone.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Propafenone.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Propafenone.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Propafenone.]
[C04AE04, dihydroergocristine, Propafenone may increase the vasoconstricting activities of Dihydroergocristine.]
[N02CA01, dihydroergotamine, Propafenone may increase the vasoconstricting activities of Dihydroergotamine.]
[J05AE08, atazanavir, The metabolism of Propafenone can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Propafenone may decrease the antihypertensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Propafenone.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Propafenone.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Propafenone.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Propafenone.]
[M02AX03, dimethyl sulfoxide, The metabolism of Propafenone can be decreased when combined with Dimethyl sulfoxide.]
[N06BC02, propentofylline, The serum concentration of Propentofylline can be increased when it is combined with Propafenone.]
[N02BB04, propyphenazone, Propyphenazone may decrease the antihypertensive activities of Propafenone.]
[M01AB14, proglumetacin, Proglumetacin may decrease the antihypertensive activities of Propafenone.]
[R03DA03, proxyphylline, The serum concentration of Proxyphylline can be increased when it is combined with Propafenone.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Propafenone.]
[C09AA06, quinapril, Propafenone may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, Dipyridamole may increase the bradycardic activities of Propafenone.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Propafenone is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Propafenone is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Cisapride.]
[C09AA05, ramipril, Propafenone may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Propafenone.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Propafenone.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Propafenone.]
[C01BA03, disopyramide, Propafenone may increase the arrhythmogenic activities of Disopyramide.]
[N07AA03, distigmine, Distigmine may increase the bradycardic activities of Propafenone.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Propafenone.]
[S02AA12, rifamycin SV, The metabolism of Propafenone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Propafenone can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Propafenone.]
[N07XX02, riluzole, The metabolism of Riluzole can be decreased when combined with Propafenone.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Propafenone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Propafenone.]
[N01BB09, ropivacaine, The metabolism of Ropivacaine can be decreased when combined with Propafenone.]
[J01MB01, rosoxacin, The metabolism of Propafenone can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be increased when used in combination with Propafenone.]
[A04AD12, aprepitant, The metabolism of Propafenone can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Propafenone.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Propafenone.]
[J05AE07, fosamprenavir, The serum concentration of Propafenone can be increased when it is combined with Fosamprenavir.]
[G04BE08, tadalafil, Propafenone may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, Ketorolac may decrease the antihypertensive activities of Propafenone.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Propafenone.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Propafenone.]
[N02BA06, salsalate, Salsalate may decrease the antihypertensive activities of Propafenone.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Propafenone.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Propafenone.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Propafenone.]
[N06AA16, dothiepin, The metabolism of Propafenone can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Propafenone.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Propafenone.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Propafenone.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Propafenone.]
[N06AB06, sertraline, Sertraline may increase the QTc-prolonging activities of Propafenone.]
[N01AB08, sevoflurane, The risk or severity of hypertension can be increased when Propafenone is combined with Sevoflurane.]
[N05AD08, droperidol, Propafenone may increase the orthostatic hypotensive activities of Droperidol.]
[A08AA10, sibutramine, The serum concentration of Propafenone can be increased when it is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Propafenone.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Propafenone.]
[C09AA11, spirapril, Propafenone may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The serum concentration of Dyphylline can be increased when it is combined with Propafenone.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Propafenone.]
[V04CX07, edrophonium, Edrophonium may increase the bradycardic activities of Propafenone.]
[C07AB13, talinolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Temafloxacin.]
[M01AC02, tenoxicam, Tenoxicam may decrease the antihypertensive activities of Propafenone.]
[G04CA03, terazosin, Propafenone may increase the orthostatic hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Propafenone can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, Propafenone may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Tertatolol.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Propafenone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Propafenone.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Propafenone is combined with Tianeptine.]
[C09AA02, enalapril, Propafenone may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the antihypertensive activities of Propafenone.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Propafenone is combined with Toloxatone.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Propafenone.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Toremifene.]
[C03CA04, torsemide, Propafenone may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Propafenone is combined with Tramazoline.]
[C09AA10, trandolapril, Propafenone may decrease the antihypertensive activities of Trandolapril.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Propafenone.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Propafenone.]
[N01AB04, enflurane, Enflurane may increase the cardiodepressant activities of Propafenone.]
[C02CA06, urapidil, Propafenone may increase the orthostatic hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The metabolism of Propafenone can be decreased when combined with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Propafenone can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Propafenone.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Propafenone.]
[N06AX16, venlafaxine, The serum concentration of Venlafaxine can be increased when it is combined with Propafenone.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Propafenone.]
[S01GA03, xylometazoline, Propafenone may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Propafenone may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Propafenone.]
[C09AA15, zofenopril, Propafenone may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Propafenone.]
[M01AB04, zomepirac, Zomepirac may decrease the antihypertensive activities of Propafenone.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Propafenone.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Propafenone.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Propafenone.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Propafenone.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Propafenone.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Propafenone.]
[C04AE01, ergoloid mesylates, USP, Propafenone may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Propafenone can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Propafenone.]
[H05BX01, cinacalcet, The metabolism of Propafenone can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Propafenone.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Propafenone.]
[J04AK02, ethambutol, The metabolism of Propafenone can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Propafenone.]
[C01CA15, gepefrine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Gepefrine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Propafenone.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Propafenone.]
[N04AA05, profenamine, Profenamine may increase the bradycardic activities of Propafenone.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Propafenone.]
[M01AC06, meloxicam, Meloxicam may decrease the antihypertensive activities of Propafenone.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Propafenone.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Propafenone.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Propafenone.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Propafenone.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Propafenone.]
[C01BA05, ajmaline, Propafenone may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Propafenone.]
[A02BA04, nizatidine, Nizatidine may increase the bradycardic activities of Propafenone.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Propafenone.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Propafenone.]
[R06AX12, terfenadine, The metabolism of Propafenone can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Propafenone can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Propafenone can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Propafenone.]
[C01BC08, encainide, Propafenone may increase the arrhythmogenic activities of Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Propafenone.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Propafenone.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Propafenone.]
[P02CA03, albendazole, The metabolism of Propafenone can be increased when combined with Albendazole.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Propafenone.]
[C08EA01, fendiline, Propafenone may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Propafenone.]
[M01AE04, fenoprofen, Fenoprofen may decrease the antihypertensive activities of Propafenone.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Propafenone.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Fentanyl is combined with Propafenone.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Propafenone.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Propafenone.]
[C01BC04, flecainide, Propafenone may increase the arrhythmogenic activities of Flecainide.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Propafenone is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Propafenone can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, Propafenone may increase the arrhythmogenic activities of Flunarizine.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Propafenone is combined with Melitracen.]
[V03AZ01, ethanol, The metabolism of Ethanol can be decreased when combined with Propafenone.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Propafenone.]
[N06AB03, fluoxetine, The serum concentration of Propafenone can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Flupentixol.]
[N05AB02, fluphenazine, The serum concentration of Propafenone can be increased when it is combined with Fluphenazine.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the antihypertensive activities of Propafenone.]
[N05AG01, fluspirilene, Propafenone may increase the arrhythmogenic activities of Fluspirilene.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Propafenone.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Propafenone.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Propafenone.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Furazolidone is combined with Propafenone.]
[J05AE10, darunavir, The metabolism of Propafenone can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Propafenone may decrease the antihypertensive activities of Furosemide.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Propafenone.]
[C08DA02, gallopamil, Propafenone may increase the arrhythmogenic activities of Gallopamil.]
[N03AA04, barbexaclone, The serum concentration of Propafenone can be decreased when it is combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Propafenone can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Propafenone.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Propafenone.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Propafenone.]
[C01CA21, cafedrine, The serum concentration of Cafedrine can be increased when it is combined with Propafenone.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Propafenone.]
[A12AA13, calcium citrate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium citrate.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium lactate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Propafenone may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Alfentanil is combined with Propafenone.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Propafenone.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Propafenone.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Propafenone.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Propafenone.]
[H04AA01, glucagon, The therapeutic efficacy of Propafenone can be decreased when used in combination with Glucagon.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Propafenone.]
[C05AE01, nitroglycerin, Propafenone may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, Propafenone may increase the arrhythmogenic activities of Dofetilide.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Propafenone.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Propafenone.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Propafenone.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Esmolol.]
[C09AA09, fosinopril, Propafenone may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Guanethidine may increase the hypotensive activities of Propafenone.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Propafenone.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Halothane is combined with Propafenone.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Propafenone.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Propafenone.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Propafenone.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Propafenone.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Propafenone.]
[A07EC02, mesalamine, Mesalazine may decrease the antihypertensive activities of Propafenone.]
[N05CA16, hexobarbital, The serum concentration of Propafenone can be decreased when it is combined with Hexobarbital.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Propafenone.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Propafenone.]
[C08CA10, nilvadipine, Propafenone may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the antihypertensive activities of Propafenone.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Oxatomide.]
[C09AA04, perindopril, Propafenone may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Propafenone may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Propafenone may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Propafenone.]
[C03AA02, hydroflumethiazide, Propafenone may decrease the antihypertensive activities of Hydroflumethiazide.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Propafenone.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Propafenone.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Propafenone.]
[G04BD06, propiverine, Propafenone may increase the orthostatic hypotensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Propafenone.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Propafenone.]
[R02AX02, ibuprofen, Ibuprofen may decrease the antihypertensive activities of Propafenone.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Propafenone.]
[H01AC02, somatrem, The metabolism of Propafenone can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Sufentanil is combined with Propafenone.]
[N06AA02, imipramine, The metabolism of Propafenone can be decreased when combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Terlipressin.]
[M03BX02, tizanidine, The serum concentration of Tizanidine can be increased when it is combined with Propafenone.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Propafenone.]
[C03BA11, indapamide, Propafenone may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, Indomethacin may decrease the antihypertensive activities of Propafenone.]
[C02CA02, indoramin, Propafenone may increase the orthostatic hypotensive activities of Indoramin.]
[L03AB04, interferon alfa-2a, The metabolism of Propafenone can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Propafenone can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The serum concentration of Propafenone can be increased when it is combined with Milnacipran.]
[S01XA28, varenicline, The risk or severity of adverse effects can be increased when Propafenone is combined with Varenicline.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Propafenone.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Propafenone.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Propafenone.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Propafenone.]
[C10AA06, cerivastatin, The metabolism of Propafenone can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Alprenolol.]
[L03AB09, interferon alfacon-1, The metabolism of Propafenone can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Propafenone.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Propafenone is combined with Iprindole.]
[N06AF05, iproniazid, The metabolism of Propafenone can be decreased when combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Propafenone.]
[N05AA07, chlorproethazine, The serum concentration of Propafenone can be increased when it is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Propafenone is combined with Isocarboxazid.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Propafenone.]
[C09AA16, imidapril, Propafenone may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of hypertension can be increased when Isoflurane is combined with Propafenone.]
[S01EB07, isoflurophate, Isoflurophate may increase the bradycardic activities of Propafenone.]
[N04BX02, entacapone, The metabolism of Propafenone can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Propafenone can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Propafenone.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Propafenone.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Propafenone.]
[N06AX18, reboxetine, The metabolism of Propafenone can be decreased when combined with Reboxetine.]
[H01AC01, somatropin, The metabolism of Propafenone can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Propafenone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the bradycardic activities of Propafenone.]
[C02KD01, ketanserin, Propafenone may decrease the antihypertensive activities of Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Propafenone can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Propafenone can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be decreased when combined with Propafenone.]
[M02AA10, ketoprofen, Ketoprofen may decrease the antihypertensive activities of Propafenone.]
[V03AC03, deferasirox, The serum concentration of Propafenone can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Propafenone can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Mizolastine.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Propafenone.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Propafenone.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Propafenone.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the antihypertensive activities of Propafenone.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Propafenone is combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Propafenone.]
[C02AA05, deserpidine, Deserpidine may increase the hypotensive activities of Propafenone.]
[N07AA30, ambenonium, Ambenonium may increase the bradycardic activities of Propafenone.]
[N03AX18, lacosamide, Propafenone may increase the bradycardic activities of Lacosamide.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Propafenone.]
[C08EX01, lidoflazine, Propafenone may increase the arrhythmogenic activities of Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Propafenone can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Propafenone.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Propafenone.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Propafenone is combined with Lofepramine.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Propafenone.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium pangamate.]
[C10AA02, lovastatin, The metabolism of Propafenone can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Propafenone.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the arrhythmogenic activities of Propafenone.]
[L01EA03, nilotinib, The metabolism of Propafenone can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Propafenone.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Propafenone.]
[C02BB01, mecamylamine, Propafenone may decrease the antihypertensive activities of Mecamylamine.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the bradycardic activities of Propafenone.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Propafenone.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the antihypertensive activities of Propafenone.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Propafenone.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Propafenone.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Dalteparin.]
[N05CH01, melatonin, The metabolism of Melatonin can be decreased when combined with Propafenone.]
[N06DX01, memantine, Memantine may increase the bradycardic activities of Propafenone.]
[C01CA11, mephentermine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Propafenone.]
[N03AA01, mephobarbital, The serum concentration of Propafenone can be decreased when it is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The serum concentration of Mepivacaine can be increased when it is combined with Propafenone.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Propafenone.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Propafenone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Propafenone.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Propafenone.]
[H01CB03, lanreotide, Propafenone may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Propafenone.]
[N06BA03, methamphetamine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Metamfetamine.]
[G02CB05, metergoline, Propafenone may increase the vasoconstricting activities of Metergoline.]
[H03BB02, methimazole, The excretion of Propafenone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be decreased when combined with Propafenone.]
[N05CA15, methohexital, The serum concentration of Propafenone can be decreased when it is combined with Methohexital.]
[N02BG08, ziconotide, Propafenone may increase the arrhythmogenic activities of Ziconotide.]
[N05AA02, methotrimeprazine, The metabolism of Methotrimeprazine can be decreased when combined with Propafenone.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Propafenone.]
[D05BA02, methoxsalen, The metabolism of Propafenone can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Propafenone.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Propafenone.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Propafenone.]
[G02AB01, methylergonovine, Propafenone may increase the vasoconstricting activities of Methylergometrine.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be increased when it is combined with Propafenone.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Propafenone.]
[N02CA04, methysergide, Propafenone may increase the vasoconstricting activities of Methysergide.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be decreased when combined with Propafenone.]
[C03BA08, metolazone, Propafenone may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Propafenone.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Propafenone.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Propafenone.]
[S02AA13, miconazole, The metabolism of Propafenone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the antihypertensive activities of Propafenone.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Parnaparin.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Propafenone.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be increased when used in combination with Propafenone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Tinzaparin.]
[C09CA03, valsartan, Propafenone may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Propafenone may decrease the antihypertensive activities of Minoxidil.]
[L01XX23, mitotane, The metabolism of Propafenone can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Lisdexamfetamine.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Propafenone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Propafenone.]
[N02AA01, morphine, The serum concentration of Morphine can be increased when it is combined with Propafenone.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Propafenone.]
[L04AB05, certolizumab pegol, The metabolism of Propafenone can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Propafenone.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Ammonium chloride.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Propafenone.]
[N05CA02, amobarbital, The serum concentration of Propafenone can be decreased when it is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Propafenone.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Propafenone.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Propafenone.]
[N03AB05, fosphenytoin, The metabolism of Propafenone can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Propafenone can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Propafenone is combined with Ropinirole.]
[J01CF06, nafcillin, The metabolism of Propafenone can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Propafenone can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Propafenone can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Propafenone.]
[N06BA01, amphetamine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the antihypertensive activities of Propafenone.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Propafenone.]
[N06AX21, duloxetine, The metabolism of Propafenone can be decreased when combined with Duloxetine.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Remifentanil is combined with Propafenone.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Propafenone.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Propafenone.]
[S01EB06, neostigmine, Neostigmine may increase the bradycardic activities of Propafenone.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Propafenone.]
[N06AX23, desvenlafaxine, The serum concentration of Propafenone can be increased when it is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Propafenone may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The metabolism of Propafenone can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Propafenone is combined with Nialamide.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Propafenone.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Propafenone.]
[P02DA01, niclosamide, The metabolism of Propafenone can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Propafenone is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Propafenone.]
[M02AA17, niflumic acid, Niflumic acid may decrease the antihypertensive activities of Propafenone.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Propafenone.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Propafenone.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Propafenone.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Propafenone.]
[C02DD01, nitroprusside, Propafenone may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Propafenone is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Propafenone.]
[S01AE02, norfloxacin, The metabolism of Propafenone can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, Propafenone may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Propafenone.]
[L03AB07, interferon beta-1a, The metabolism of Propafenone can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, Propafenone may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Propafenone.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Propafenone.]
[L04AC04, rilonacept, The metabolism of Propafenone can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Propafenone can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Propafenone is combined with Opipramol.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Propafenone.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Propafenone.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Propafenone.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Propafenone.]
[P02BA02, oxamniquine, The metabolism of Propafenone can be decreased when combined with Oxamniquine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Propafenone.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Propafenone.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Propafenone.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propafenone.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Propafenone.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the antihypertensive activities of Propafenone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propafenone.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Propafenone is combined with Danaparoid.]
[M03AC01, pancuronium, Pancuronium may increase the bradycardic activities of Propafenone.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Propafenone.]
[C02KC01, pargyline, Propafenone may decrease the antihypertensive activities of Pargyline.]
[J01MA03, pefloxacin, The metabolism of Propafenone can be decreased when combined with Pefloxacin.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Propafenone.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Penbutolol.]
[N05AG03, penfluridol, Propafenone may increase the arrhythmogenic activities of Penfluridol.]
[N05CA01, pentobarbital, The metabolism of Propafenone can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The serum concentration of Pentoxifylline can be increased when it is combined with Propafenone.]
[N05AB10, perazine, The serum concentration of Propafenone can be increased when it is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Propafenone.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Propafenone.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Propafenone.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Propafenone.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Phenelzine is combined with Propafenone.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Propafenone.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Propafenone.]
[N03AA02, phenobarbital, The metabolism of Propafenone can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, Propafenone may increase the orthostatic hypotensive activities of Phenoxybenzamine.]
[A08AA01, phentermine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Propafenone may increase the orthostatic hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the antihypertensive activities of Propafenone.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Propafenone.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Propafenone.]
[N03AB02, phenytoin, The metabolism of Propafenone can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Propafenone can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Propafenone.]
[V03AB19, physostigmine, Physostigmine may increase the bradycardic activities of Propafenone.]
[C08CX01, mibefradil, Propafenone may increase the arrhythmogenic activities of Mibefradil.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Propafenone is combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Propafenone.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Pindolol.]
[J05AE01, saquinavir, The metabolism of Propafenone can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Propafenone.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Propafenone.]
[C09CA02, eprosartan, Propafenone may decrease the antihypertensive activities of Eprosartan.]
[S01BC06, piroxicam, Piroxicam may decrease the antihypertensive activities of Propafenone.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Grepafloxacin.]
[N02CX01, pizotyline, Propafenone may increase the orthostatic hypotensive activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Propafenone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Propafenone may decrease the antihypertensive activities of Irbesartan.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Propafenone.]
[A03AE01, alosetron, The metabolism of Propafenone can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Propafenone can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Propafenone may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Propafenone can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Propafenone.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Propafenone.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Propafenone.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Propafenone.]
[C07AB01, practolol, The risk or severity of adverse effects can be increased when Propafenone is combined with Practolol.]
[C01BA08, prajmaline, Propafenone may increase the arrhythmogenic activities of Prajmaline.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Propafenone.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Propafenone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Antazoline.]
[C01DX02, prenylamine, Propafenone may increase the arrhythmogenic activities of Prenylamine.]
[P01BA03, primaquine, The metabolism of Propafenone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Propafenone can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Probucol.]
[C01BA02, procainamide, Propafenone may increase the arrhythmogenic activities of Procainamide.]
[S01HA05, procaine, Procaine may increase the bradycardic activities of Propafenone.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Propafenone.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Propafenone.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Propafenone.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Propafenone.]
[N05AC01, periciazine, The serum concentration of Propafenone can be increased when it is combined with Periciazine.]
[N05CM06, propiomazine, Propafenone may increase the orthostatic hypotensive activities of Propiomazine.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Propafenone.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Propofol is combined with Propafenone.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Propafenone.]
[C07AA05, propranolol, The serum concentration of Propafenone can be increased when it is combined with Propranolol.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Propafenone.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Rizatriptan is combined with Propafenone.]
[B01AC09, epoprostenol, Propafenone may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Protriptyline is combined with Propafenone.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Propafenone can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Propafenone.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Propafenone.]
[N07AA02, pyridostigmine, Pyridostigmine may increase the bradycardic activities of Propafenone.]
[R06AC01, pyrilamine, The metabolism of Propafenone can be decreased when combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may decrease the QTc-prolonging activities of Propafenone.]
[P01BC01, quinine, The metabolism of Propafenone can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Propafenone can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Propafenone may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Reserpine may increase the hypotensive activities of Propafenone.]
[J04AB02, rifampin, The metabolism of Propafenone can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Propafenone.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Propafenone.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Propafenone.]
[N02BA05, salicylamide, Salicylamide may decrease the antihypertensive activities of Propafenone.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the antihypertensive activities of Propafenone.]
[S01BC08, salicylic acid, Salicylic acid may decrease the antihypertensive activities of Propafenone.]
[N05CA06, secobarbital, The serum concentration of Propafenone can be decreased when it is combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Propafenone.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Propafenone is combined with Sotalol.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Propafenone.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Propafenone.]
[M03BX02, tizanidine, Tizanidine - CYP 1A2 inhibitors]
